

000 001 MEDINSIGHTBENCH: EVALUATING MEDICAL ANA- 002 LYTICS AGENTS THROUGH MULTI-STEP INSIGHT DIS- 003 COVERY IN MULTI-MODAL MEDICAL DATA 004 005

006 **Anonymous authors**

007 Paper under double-blind review
008
009
010

011 ABSTRACT 012

013 In medical data analysis, extracting deep insights from complex, multi-modal
014 datasets is essential for improving patient care, increasing diagnostic accuracy,
015 and optimizing healthcare operations. However, there is currently a lack of high-
016 quality datasets specifically designed to evaluate the ability of large multi-modal
017 models (LMMs) to discover medical insights. In this paper, we introduce MedIn-
018 sightBench, the first benchmark that comprises 332 carefully curated medical
019 cases [from cancer genomics atlas data](#), each annotated with thoughtfully designed
020 insights. This benchmark is intended to evaluate the ability of LMMs and agent
021 frameworks to analyze multi-modal medical image data, including posing relevant
022 questions, interpreting complex findings, and synthesizing actionable insights and
023 recommendations. Our analysis indicates that existing LMMs exhibit limited per-
024 formance on MedInsightBench, which is primarily attributed to their challenges in
025 extracting multi-step, deep insights and the absence of medical expertise. There-
026 fore, we propose MedInsightAgent, an automated agent framework for medical
027 data analysis, composed of three modules: Visual Root Finder, Analytical In-
028 sight Agent, and Follow-up Question Composer. Experiments on MedInsight-
029 Bench highlight pervasive challenges and demonstrate that MedInsightAgent can
030 improve the performance of general LMMs in medical data insight discovery.
031
032

033 1 INTRODUCTION 034

035 Recent advancements in medical data analysis using large multi-modal models (LMMs) have sig-
036 nificantly improved clinical diagnosis (Mendoza et al.; Sun et al., 2025a; Xu et al., 2024). Medical
037 insight detection that transforms heterogeneous data (e.g., pathological images) into actionable
038 insights is crucial to improve diagnostic accuracy, guide treatment decisions, and enable new scientific
039 discoveries (Zhan et al., 2025; Lu et al., 2024).

040 Despite recent strides in LMMs for combined visual–language reasoning (Mendoza et al.; Sun et al.,
041 2025a; Xu et al., 2024), their diagnostic accuracy and medical insight detection in real-world clin-
042 ical settings remains limited (Fan et al., 2025; Schmidgall et al., 2024). Existing benchmarks mainly
043 probe surface-level competencies, such as retrieving overt facts or answering direct questions (Pandit
044 et al., 2025; Shang et al., 2025). They overlook higher-order clinical cognition, which includes un-
045 covering occult pathological relationships, formulating pathophysiologically grounded hypotheses,
046 and integrating multi-modal evidence for prognostic inference (Wu et al., 2025; Tang et al., 2025).
047 Therefore, there is a requirement for benchmarks that can assess whether LMMs can automatically
048 discover, synthesize, and generate reliable, clinically meaningful insights from pathology data.

049 To facilitate a comprehensive evaluation of insight discovery in pathology, we propose MedInsight-
050 Bench, a novel benchmark that includes high-quality medical images, explicit analytical goals to
051 guide exploration, and question-insight pairs. MedInsightBench comprises 332 cases and 3,933 in-
052 sights across six categories, utilizing a raw dataset from public cancer pathology resources. Our
053 methodology involves downsampling WSI files to PNGs, segmenting report text into related evi-
054 dence snippets with human verification, and deriving concise analysis goals from the logical rela-
055 tionships among the generated questions. Based on MedInsightBench, we conducted a comprehen-
056 sive evaluation of five LMMs, assessing their effectiveness in insight discovery within pathology.

The evaluation of LMMs, such as GPT-4o (OpenAI, 2024) and Deepseek-VL2 (Wu et al., 2024), on MedInsightAgent reveals significant limitations. LMMs often struggle with multi-step analytical workflows that require image parsing, statistical reasoning, domain-constrained inference, and verifiability. Furthermore, LMMs show limited domain expertise, unstable chain-of-thought reasoning, and poor interpretability, all of which impact insight reliability and clinical utility. To address these issues, we propose MedInsightAgent, a multi-agent collaborative framework that has three main components: (i) Visual Root Finder extracts key image cues and background knowledge to generate initial root questions; (ii) Analytical Insight Agent analyzes image regions for each question to produce grounded answers and insights; and (iii) Follow-Up Question Composer generates iterative, derivative questions to enable deeper and more exploratory discovery. Agents exchange constrained information and iterate to produce deeper, more reliable, and more interpretable insights.

In our experiments, we benchmark multiple LMMs and agent frameworks on MedInsightBench using a comprehensive evaluation protocol, including Insight Recall, Precision, $F1$, and Novelty. The results highlight key challenges in automated medical insight discovery and show that our MedInsightAgent significantly enhances the insight discovery performance of base LMMs. In summary, our contributions are as follows.

- We introduce a novel multi-modal benchmark for the discovery of medical insight. The data set pairs pathology images with text and includes hierarchical tasks and validated metrics to assess the quality of knowledge.
- We design a multi-agent collaborative framework for insight discovery. The framework formalizes agent roles and interaction protocols to combine local visual analysis, cross-sample inference, and domain knowledge.
- We provide extensive empirical analysis on several baseline LMMs and on our multi-agent system. The experiments show the discriminative power of the benchmark and demonstrate that the multi-agent approach improves the precision and interpretability of the information.

2 RELATED WORKS

2.1 MEDICAL DATA ANALYSIS

Recent research has introduced benchmarks and frameworks for evaluating large language models (LLMs) and agent systems on medical reasoning and data analysis tasks. Several datasets emphasize multi-step clinical reasoning and multi-modal expert questions, including MedAgentsBench (Tang et al., 2025), MedAgentBench (Jiang et al., 2025), MedCaseReasoning (Wu et al., 2025), MedXpertQA (Zuo et al., 2025), and the Chinese CMB (Wang et al., 2024). Other work addresses interactive clinical workflows and multi-agent collaboration. AI Hospital (Fan et al., 2025), Agent-Clinic (Schmidgall et al., 2024), 3MDBench (Sviridov et al., 2025), and MedChain (Liu et al., 2024) simulate multturn patient-clinician interactions, while MMedAgent-RL (Xia et al., 2025), MedAgentBoard (Zhu et al., 2025), and the MAD framework (Smit et al., 2023) explore multi-agent training and collaboration strategies, finding that multi-agents do not always outperform strong LMM. Finally, some studies address evaluation gaps and modality-specific challenges, such as MedHallu (Pandit et al., 2025), which focuses on hallucination detection, and work that disentangles knowledge from reasoning to expose benchmark inflation. MedRepBench (Shang et al., 2025) evaluates vision-language models to interpret complex medical reports, and Med3DInsight (Chen et al., 2025) improves 3D image understanding by leveraging 2D LMM pretraining. In contrast, our work centers on multi-step and in-depth explorative insight discovery in the medical domain, pushing the boundaries of traditional evaluations to uncover deeper, more nuanced insights.

2.2 DATA INSIGHT AGENTS AND BENCHMARKS

Some work on LLM-driven data analysis has produced benchmarks, datasets, and agentic frameworks that move beyond single-query answers to multi-step analytical workflows. Text-to-SQL efforts include FinSQL (Zhang et al., 2024), Spider 2.0 (Lei et al., 2024), EHRSQL (Lee et al., 2022), and PRACTIQ (Dong et al., 2025), which address domain-specific querying, complex multi-step SQL, and conversational ambiguity. For visualization, VisEval (Chen et al., 2024a) offers a large evaluation system, while MatPlotAgent (Yang et al., 2024) and nvAgent (Ouyang et al., 2025) propose multi-agent workflows to iteratively generate and validate visualizations, showing signif-




Figure 1: The dataset construction pipeline of MedInsightBench. This pipeline consists of 3 steps: 1) **Pathological Image Processing.** WSIs are standardized and quality-checked. 2) **Report Processing & Insight Extraction.** Reports are converted to text, insights and questions are generated, and verified by experts. 3) **Goal Generation.** An overarching analysis goal is synthesized from the questions and validated for guiding the analysis.

licant improvements. In addition, InfiAgent-DABench (Hu et al., 2024) introduces a broad benchmark for assessing LLM-based data analysis agents, and DAgent (Xu et al., 2025) extends this by generating complete analytical reports from relational databases. Other works target end-to-end insight generation. For example, InsightBench (Sahu et al., 2025), InsightPilot (Ma et al., 2023), InsightLens (Weng et al., 2025), and an LLM-based SQL decomposition approach (Pérez et al., 2025) cover multi-step discovery, autonomous exploration, and insight organization. Our MedInsightBench is the first comprehensive and high-quality benchmark for medical insight discovery.

3 MEDICAL INSIGHT BENCHMARK

3.1 PRELIMINARY STUDY OF INSIGHT DISCOVERY TASK

In the insight discovery task, there are a variety of viable approaches. For tabular data insights, multi-agent pipelines have proven particularly effective. Two state-of-the-art multi-agent paradigms are Pérez et al. (Pérez et al., 2025), which uses SQL to extract information from structured tables, and Agent Poirot (Sahu et al., 2025), which relies on Python scripts and standard data-analysis libraries to retrieve the relevant statistics and evidence.

For insight discovery in image-modal data, we considered both LMM and agentic framework paradigms. Given an image and a pre-specified goal, LMM can directly produce a set of analytical insights after reasoning. By contrast, a multi-agent pipeline proceeds in multiple steps: it generates a sequence of goal-directed questions, answers those questions, and finally synthesizes insights.

Guided by InsightBench (Sahu et al., 2025), we identified several design requirements for a high-quality medical image-based insight benchmark:

- 1. Medical image quality and completeness:** The images must clearly and fully depict the target content so that relevant features are observable.
- 2. Explicit analytical goal:** The analysis goal must be unambiguous and state the intended focus, such as relevant comparison metrics, axes, or dimensions of analysis, etc.
- 3. Question-insight consistency:** Each insight must be supported by a clear, well-formed question and grounded in solid evidence. The questions should be comprehensive and multidimensional, while the insights should be meaningful, informative, and well-rounded.

162 Based on these principles, we constructed a novel medical insight discovery benchmark. The dataset
 163 construction pipeline is described in detail in the next section.
 164

165 **3.2 DATA CONSTRUCTION**

166 From our preliminary study, we identified the key priorities and objectives for dataset construction:
 167 (i) high-quality and comprehensive medical images; (ii) an explicit and well-specified analytical
 168 goal; (iii) comprehensive, in-depth, multi-dimensional exploratory insights. Among publicly avail-
 169 able medical datasets, The Cancer Genome Atlas (TCGA) provides various types of cancer and
 170 associated patient samples. Each sample includes tumor-associated images and paired pathology
 171 reports, which align well with our requirements. Therefore, we select it as our source data.
 172

173 Our construction methodology combines mainly manual curation with LLM-assisted generation.
 174 We also performed a human review to ensure image quality and evidence validity. The overall
 175 pipeline is illustrated in Figure 1. We describe each step of the pipeline in detail as follows.
 176

177 **3.2.1 STEP 1: PATHOLOGICAL IMAGE PROCESSING**

178 In the TCGA repository, each pathological whole-slide image (WSI) is stored as SVS. To convert
 179 WSI into suitable inputs for LMMs, we applied a standardized image processing pipeline. First, we
 180 instantiate a slide object and extract essential metadata such as pixel spacing and the dimensions
 181 of each pyramid level. Next, to preserve the global structure and large-scale morphological features
 182 while reducing the WSI to an acceptable size, we perform whole-slide downsampling. Given a target
 183 maximum output dimension, we compute an appropriate downsample ratio and select the optimal
 184 pyramid level. After color normalization, the images are exported as PNGs for downstream use.
 185

186 To ensure that the final images are clear, complete and usable, we also utilize an automated check
 187 using an LMM combined with manual review. This step filters out images that are unreadable or
 188 corrupted and yields a curated set of pathological images suitable for data analysis.
 189

190 **3.2.2 STEP 2: PATHOLOGICAL REPORT PROCESSING AND INSIGHT EXTRACTION**

191 We first retrieve the corresponding pathology reports (PDF) from the TCGA repository based on the
 192 case name of each sample. Next, we convert the reports to plain text through OCR and then inspect
 193 and correct them through LLM assistance and human verification. We inspect each report based on
 194 multiple quality criteria, including the absence of invalid characters or corrupted content, coherence
 195 of diagnostic statements, and alignment between textual descriptions and expected clinical content.
 196 Therefore, insight generation from plain-text reports is carried out in four stages as follows:
 197

1. **Report Decomposition:** We apply an LLM to extract the key items of the report, represented as
 200 a sequence of evidence snippets that form a progressive, interrelated chain of findings.
2. **Insight Generation:** Guided by six insight types (details in Appendix A.2), we analyze each
 202 evidence and employ an LLM to generate insights. Moreover, we compute a confidence score
 203 for each insight to indicate quality, and those insights with low confidence are manually filtered.
3. **Analytical Questions Generation:** To enhance analytical depth and hierarchy, we pose goal-
 204 directed questions for each insight, ensuring a logical progression that enables incremental dis-
 205 covery of deeper and meaningful findings.
4. **Human Verification:** We reviewed the questions, insights, and their corresponding evidence
 207 excerpt to confirm logical consistency, factual accuracy, and rationality.

208 **3.2.3 STEP 3: GOAL GENERATION**

209 The analytical goal has two key properties: (i) it must be clearly and unambiguously stated. (ii)
 210 effectively guide both the generation of analysis questions and the overall analytical strategy. We
 211 analyze the logical relationships and dependencies among these generated questions and synthesize
 212 a concise, overarching analysis goal. To avoid hallucinations or misinterpretations, each generated
 213 goal is subject to human verification. We retained goals that are precise, coherent with the underlying
 214 questions, and appropriate to guide downstream analyses.
 215

(a) Quality Assessment			(b) Redundancy Assessment		
Dimension	LLM Eval	Human Annotation	Metric	Questions	Insights
Correctness	0.906	0.919	TC Similarity	0.0555	0.0307
Rationality	0.876	0.891	Self-BLEU	0.2285	0.0698
Coherence	0.910	0.930	Distinct-2	0.7748	0.9355

Table 1: Data quality and redundancy analysis of MedInsightBench.

Dataset	Input	Output	Topic & Area	Data Size	Construction Method
Spider 2.0 Lei et al. (2024)	Question	SQL Query	Enterprise-level	632	Machine & Human-Labeled
MatPlotBench Yang et al. (2024)	Question+Table	Vis Image	Data Visualization	100	Machine & Human-Labeled
Infini-Agent-DABench Hu et al. (2024)	Question+Table	Answer	Data Analysis	603	Machine-Labeled
MedAgentsBench Tang et al. (2025)	Question	Answer	Clinical Analysis	862	Existed Dataset Combined
InsightBench Sahu et al. (2025)	Goal+Table	Insights	Business Analysis	100	Human-Labeled
MedInsightBench	Goal+Image	Insights	Medical Analysis	332	Machine-Labeled & Human-Verified

Table 2: Comparison of MedInsightBench with other existing benchmarks.

3.3 EVALUATION FRAMEWORK

Current insights discovery evaluations are predominantly based on automated text matching metrics and G-Eval scoring, with InsightBench (Sahu et al., 2025) further narrowing the assessment to a single LLM evaluator, introducing the risk of amplifying inherent biases. Furthermore, existing protocols only compare predicted outputs with annotated ground-truth, disregarding hallucinated or incorrect predictions, while failing to identify the novel and unannotated insights. To address these limitations, we propose a refined automated evaluation framework that more accurately reflects analytical capability through four complementary metrics: **Insight Recall**, **Insight Precision**, **Insight F1-score**, and **Insight Novelty**. This approach enables explicit assessment of correct retrieval, error rates, overall balance, and discovery of previously unrecognized insights. The details of each evaluation metric are described in Appendix B.

3.4 DATA QUALITY ANALYSIS

To verify the quality of the dataset, we conducted an in-depth annotation across three dimensions:

- **Correctness**: whether each set of questions strictly corresponds to the stated goal and the pathological images without factual errors.
- **Rationality**: whether each insight satisfies the goal’s requirements and is logically sound.
- **Coherence**: whether insights in each case are internally consistent and mutually compatible.

We randomly sampled 100 instances and annotated them by both LMM (i.e., OpenAI o3) and human experts, computing the accuracy rate for each dimension. The results are reported in Table 1a.

In addition, we evaluated redundancy for each question and insight using three metrics. First, we compute cosine similarity based on TF-IDF vector representations and average the resulting scores. Second, we computed Self-BLEU (Zhu et al., 2018) for each sentence to assess n-gram repetitiveness. Third, we measured Distinct-2, defined as the ratio of unique bigrams to total bigrams across all sentences. Generally, a higher TF-IDF cosine similarity and Self-BLEU indicate greater redundancy, while a Distinct-2 value closer to 1 reflects greater lexical diversity and lower redundancy. Table 1b reports these redundancy statistics. Through this rigorous quality assurance process, our dataset meets a high standard of reliability and scholarly validity.

3.5 BENCHMARK STATISTIC

The MedInsightBench dataset comprises 332 samples, each of which contains a single cancer pathology image, a specific goal, and several medical insights, yielding a total of 3,933 insights across the dataset. Each sample is annotated with one of the four difficulty levels. Furthermore, each insight is labeled with an insight category, an associated question, and an excerpt of evidence drawn from the original report. In addition, compared to other well-regarded datasets, MedInsightBench stands out for its large-scale image-modal insights, which are displayed in Table 2.




Figure 2: The overall workflow of MedInsightAgent. The framework consists of three main components: Visual Root Finder, Analytical Insight Agent, and Follow-Up Question Composer.

4 MEDINSIGHTAGENT: A MULTI-AGENT FRAMEWORK FOR MEDICAL INSIGHT DISCOVERY

Due to the suboptimal performance and inherent limitations of LMM in medical insight discovery tasks, we design a multi-agent framework named MedInsightAgent. The framework decomposes the insight discovery process into three specialized agents: 1) **Visual Root Finder**: Given the analytical goal, analyze the image, summarize, identify salient visual features, and generate an initial set of root questions. 2) **Analytical Insight Agent**: Answer each question using the image and associated evidence, and finally generate medical insights. 3) **Follow-up Question Composer**: Generate follow-up questions that probe deeper or explore complementary perspectives to refine and extend the discovered insights. The overall architecture is illustrated in Figure 2. We describe the processing flow and implementation details of each agent as follows.

4.1 VISUAL ROOT FINDER

The Visual Root Finder (VRF) takes a medical image I and an analytical goal G as input and generates an initial set of root questions $Q = \{q_i\}_{i=1}^m$, where m is the number of questions. These root questions define the primary directions for exploration and guide subsequent insight generation.

To improve the quality of root questions, Visual Root Finder first gathers supplementary information. It incorporates two information-acquisition modules: (1) **Image-Summarization Module** \mathcal{ISM}_{img} . To broadly explore the medical image, the module performs an initial interpretation, extracting prominent visual features and observations F . Then it generates various and representative keywords K , formalized as $\mathcal{ISM}_{img} : I \mapsto (F, K)$. (2) **Web-Retrieval Module** \mathcal{WRM} . Using keywords K , this module retrieves domain knowledge by querying online resources (e.g., literature, reports) and returns the top ten relevant items $D = \mathcal{WRM}(K) = \{d_1, \dots, d_{10}\}$.

Finally, the **Root Question Generator** \mathcal{L} takes the medical image, the predefined analysis goal, and the retrieved information to produce a set of high-quality, precise, and concrete root questions that form the foundation for downstream analytical agents. The general process is formalized in Eq. 1.

$$VRF(I, G) = \mathcal{L}(I, G, F, D) \Rightarrow Q \quad (1)$$

4.2 ANALYTICAL INSIGHT AGENT

The Analytical Insight Agent (AIA) generates answers $A = \{a_i\}_{i=1}^m$ of the root questions and derives meaningful insights $S = \{s_i\}_{i=1}^m$. Since different questions probe distinct analytical facets,

324 directly interpreting the pathological image often leads to hallucinations or incomplete responses.
 325 Thus, it is essential to explicitly extract image evidence relevant to questions before answering them.
 326

327 For this targeted evidence extraction, we employ PathGen-LLaVA (Sun et al., 2025b), which is an
 328 LMM built on the LLaVA architecture and fine-tuned on the PathGen pathology dataset (Sun et al.,
 329 2025b), as an **Image-Analysis Tool** \mathcal{IAT} . For each root question q_i , it analyzes the image I and
 330 outputs relevant pathological findings and visual cues E_i , where $E_i = \mathcal{IAT}(I, q_i)$. These structured
 331 and question-specific image features serve as grounded evidence for subsequent reasoning.

332 Finally, the **Answers and Insights Generator** \mathcal{G} takes the question, the pathological image, and the
 333 extracted findings to produce a rational answer and a concise, clinically meaningful insight. The
 334 overall formula is shown in Eq. 2.

$$335 \quad 336 \quad \text{AIA}(I, Q) = \left\{ \mathcal{G}(q_i, I, E_i) \right\}_{i=1}^m \Rightarrow A, S \quad (2)$$

338 4.3 FOLLOW-UP QUESTION COMPOSER

340 The initial set of root question often suffers from coverage limitations and stochastic variability.
 341 To address this, we introduce the Follow-up Question Composer (FQC), which generates deeper
 342 and more penetrating questions for each root question. The follow-up questions $T = \{t_i\}_{i=1}^m$ must
 343 satisfy two criteria: (i) They must be relevant to the image I and aligned with the analytical goal G .
 344 (ii) They must be distinct yet logically derived from the original root question, extending the inquiry
 345 to explore additional facets of the pathological image.

346 The **Follow-Up Question Generator** \mathcal{F} first generates n candidate follow-up questions $C =$
 347 $\{c_i\}_{i=1}^n$. Then the **Question Selector** \mathcal{S} scores each candidate and selects the highest-scoring one
 348 c_{best} . The process is formalized in Eq. 3.

$$350 \quad 351 \quad \text{FQC}(I, G, Q, A, F, D) = \mathcal{S}\left(\left\{ \mathcal{F}(I, G, q_i, a_i, F, D) \right\}_{i=1}^n\right) = \mathcal{S}(C) \Rightarrow c_{best} \quad (3)$$

353 The selected follow-up question c_{best} is then passed to the Analytical Insight Agent to generate new
 354 insights. The process is controlled by an exploration depth parameter p ($p \geq 0$), which specifies
 355 the number of follow-up iteration cycles. Each root question is expanded through p rounds before
 356 termination, after which the system outputs all accumulated insights. In particular, if r root questions
 357 are generated, the total number of final insights (Ins) can be computed as $Ins = r \times (q + 1)$.

358 5 EXPERIMENTS AND ANALYSIS

360 361 5.1 EXPERIMENTAL SETUP

362 **Baselines** We evaluated the following baselines on MedInsightBench:

- 364 **Large Multi-modal Models:** We directly utilize several LMMs including GPT-4o (OpenAI,
 365 2024), GPT-5 (OpenAI, 2025), Deepseek-VL2 (Wu et al., 2024), Qwen2.5-VL-32B-Instruct (Bai
 366 et al., 2025) and InternVL3-38B (Chen et al., 2024b) to generate insights.
- 367 **React Framework:** We implemented a ReAct (Yao et al., 2023) structure agent and equipped it
 368 with external tools such as a computation module and a web-search interface.
- 369 **MedInsightAgent:** Our agent system discovers high-quality insights through an iterative loop of
 370 analysis, targeted question generation, answering, insights derivation and follow-up questioning.

371 **Agent Implementation details** In each agent framework, we use GPT-4o and Qwen2.5-VL-32B-
 372 Instruct as the backbone LMMs for MedInsightAgent and GPT-4o as the backbone for the ReAct
 373 framework. All LMMs are configured with a temperature of 0 to ensure deterministic output. In
 374 our MedInsightAgent, we run 4 rounds of iterations, with 3 new questions generated in each round.
 375 Similarly, the ReAct agent is set to generate the same number of questions to ensure rationality.

376 **Metrics** For recall and precision assessment, we employ two evaluators: ROUGE-1 (Lin, 2004) and
 377 G-Eval (Liu et al., 2023). Specifically, the G-Eval score is calculated as the average of the GPT-3.5-
 Turbo and Gemini 2.5 Pro scores. Next, Recall and Precision are calculated using Eq. 4 and 5,

378 379 380 381 382 383 384 385 386 387 388 389	Baselines	Insights Recall		Insights Precision		Insights F_1		Insights Novelty	
		ROUGE-1	G-Eval	ROUGE-1	G-Eval	ROUGE-1	G-Eval	Original	Innovation
LMM-only									
GPT-4o	0.180	0.298	0.209	0.358	0.193	0.325	0.129	0.209	
GPT-5	0.187	0.305	0.185	0.365	0.186	0.332	0.132	0.213	
Deepseek-VL2	0.183	0.323	0.228	0.407	0.203	0.360	0.196	0.271	
Qwen2.5-VL-32B-Instruct	0.192	0.398	0.214	0.485	0.202	0.437	0.349	0.417	
InternVL3-38B	0.177	0.339	0.201	0.399	0.188	0.367	0.161	0.255	
Agent Framework									
ReAct (GPT-4o)	0.181	0.302	0.203	0.371	0.192	0.332	0.142	0.224	
MedInsightAgent (GPT-4o)	0.189	0.361	0.197	0.413	0.193	0.384	0.180	0.270	
MedInsightAgent (Qwen2.5-VL)	0.212	0.451	0.209	0.546	0.211	0.494	0.416	0.478	

Table 3: Insight discovery performance of different LMMs and agents on MedInsightBench. Qwen2.5-VL represents Qwen2.5-VL-32B-Instruct.

390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431	Methods	Insights Recall	Insights Precision	Insights F_1	Insights Novelty
Direct Decoding(GPT-4o)		0.298	0.358	0.325	0.209
MedInsightAgent(GPT-4o)		0.361	0.413	0.384	0.270
w/o Image-Summarization Module		0.352	0.407	0.378	0.253
w/o Web-Retrieval Module		0.337	0.389	0.361	0.239
w/o Image-Analysis Tool		0.331	0.377	0.353	0.261
w/o Follow-Up Question Composer		0.314	0.365	0.338	0.233

Table 4: Effect of each method and module within the MedInsightAgent framework. We use the G-Eval score in Insight Recall, Precision, and F_1 metrics, and Innovation score in Insight Novelty.

with G-Eval scores normalized for direct comparison with ROUGE-1. The final insight F_1 score is derived using Eq. 6. Moreover, we sampled 100 data points and scored them by ten human experts. To measure insight novelty, we calculate both Original and Innovation scores using Eq. 7.

5.2 EXPERIMENTAL RESULTS AND FINDINGS

Model and framework performance comparison. Table 3 summarizes the performance of various LMMs and agent frameworks in MedInsightBench. Among LMM-only baselines, Deepseek-VL2 attains the highest ROUGE-1 score for the Insight F_1 metric, while Qwen2.5-VL-32B-Instruct achieves the best G-Eval performance. Consistently, MedInsightAgent built on Qwen2.5-VL-32B-Instruct delivers the strongest overall results among all evaluated agent systems.

Insight Novelty evaluation shows that Qwen2.5-VL-32B-Instruct and its MedInsightAgent achieve the highest Innovation scores in their respective baseline groups. In addition, higher Insight F_1 scores generally correspond to greater novelty. Comparison of Original and Innovation scores reveals two trends: (i) All evaluated baselines improve in Innovation relative to their Original Score. (ii) Baselines with lower Original Scores tend to exhibit larger relative gains in Innovation.

MedInsightAgent can enhance the performance of medical insight discovery. Comparing GPT-4o with its agent-augmented counterparts in Table 3, we observe that the ReAct framework yields only marginal improvement, whereas MedInsightAgent substantially enhances the performance of the base LMM. Furthermore, stronger base LMMs such as Qwen2.5-VL-32B-Instruct achieve even greater gains when integrated into our multi-agent pipeline.

High precision causing redundancy and limited exploratory depth. The Insight Precision is consistently higher than Insight Recall, suggesting that both LMMs and agents prioritize producing highly precise, well-supported insights while avoiding uncertain or exploratory outputs. Although this reduces spurious assertions, it also increases redundancy, with many high-scoring insights being repetitive. Consequently, despite the strong nominal quality of the outputs, the LMMs and agents still show limited depth and comprehensiveness of exploration.

5.3 ABLATION STUDY OF AGENT FRAMEWORK

Our MedInsightAgent introduces several new modules and tools that significantly enhance medical insight discovery. To assess the contribution of each component, we conducted an ablation study in Table 4. Removing any single component led to a measurable degradation in performance, under-

432	Ground-Truth Insight	Output of GPT-4o	Output of MedInsightAgent(GPT-4o)	
433	Case 139: TCGA-EJ-A7NM with Difficulty Level 2			
434	Lymphovascular invasion and extensive perineural invasion suggest increased metastatic potential; consider systemic therapy evaluation.	Absence of perineural invasion in the visible sections may impact staging.	Perineural invasion suggests a more aggressive tumor, which might increase the likelihood of cancer recurrence and affect treatment decisions.	
435	Multifocal extracapsular extension and seminal vesicle invasion indicate locally advanced disease with higher recurrence risk; discuss adjuvant therapy options.	Stromal desmoplasia is present, indicating possible tumor-host interaction and invasive behavior.	A strong stromal reaction, known as desmoplasia, often indicates a more aggressive tumor behavior and higher grade in prostate cancer, potentially impacting treatment strategies and prognosis.	
436	Case 122: TCGA-IN-A7NT with Difficulty Level 3			
437	Angiolymphatic invasion is present.	No definitive lymphovascular invasion observed, although detailed review and further sections may be warranted.	The presence of lymphovascular invasion can suggest a higher risk of metastasis, informing treatment decisions and prognosis.	
438	Poorly differentiated (G3) adenocarcinoma suggests more aggressive tumor biology; consider comprehensive treatment approach.	There are poorly formed glands and irregular cell clustering, which may indicate a higher histologic grade.	The presence of pronounced cellular atypia and high mitotic rate suggests a more aggressive tumor behavior, potentially correlating with a higher risk of nodal metastasis and impacting therapeutic decisions.	
439	Case 13: TCGA-05-4250 with Difficulty Level 4			
440	Poorly differentiated grade 3 tumor with lymph node metastases, vascular invasion, and R2 resection status indicates high risk of recurrence and poor prognosis; recommend multidisciplinary discussion for adjuvant therapy consideration.	The presence of irregular nests may indicate an aggressive phenotype.	These pathological features indicate aggressive tumor behavior, which is crucial for determining prognosis and guiding effective treatment strategies.	
441	Multifocal invasion of blood vessels is identified.	No clear lymphovascular invasion is observed in the current section.	This pattern of tissue invasion suggests a higher risk of cancer spreading beyond its origin, which could impact treatment strategies.	

454 Table 5: Case study of Insight Discovery. We selected three cases across different difficulty levels,
 455 with the bolded statements highlighting instances where MedInsightAgent demonstrated superior
 456 performance and the underlined parts show the defects in the output of GPT-4o.

457 scoring its importance. Specifically, the Image-Analysis Tool has the greatest impact on intrinsic
 458 quality metrics (Insight Recall, Precision, and F1). It provides targeted, goal-directed analysis of
 459 each slide, yielding the most relevant evidence for accurate responses. In contrast, omitting the
 460 Web-Retrieval Module results in a sharp decline in insight-novelty scores, highlighting the role of
 461 external domain knowledge and literature in fostering innovative discoveries.

462 Further ablations on the Follow-up Question Composer demonstrate that multi-round iteration ques-
 463 tioning is crucial for deeper exploration and more novel insights. In general, these results confirm
 464 that the coordinated integration of image analysis, external knowledge retrieval, and iterative ques-
 465 tioning is essential for comprehensive and innovative medical insight discovery.

466 5.4 CASE STUDY

467 Table 5 presents case studies of varying difficulty, comparing the ground-truth insights with outputs
 468 from GPT-4o and our MedInsightAgent (GPT-4o). The GPT-4o output often exhibits internal con-
 469 tradictions, incorrect judgments, and omissions of key information. In contrast, MedInsightAgent
 470 (GPT-4o) typically produces more accurate and well-grounded insights, although some outputs re-
 471 main overly conceptual. These results illustrate the limitations of MedInsightBench, which demands
 472 a more domain-specific medical knowledge in the base LMMs.

473 6 CONCLUSION AND FUTURE WORK

474 We propose MedInsightBench, a novel benchmark for the rigorous and precise evaluation of
 475 medical-insight discovery. The benchmark supports automated evaluation and demonstrates strong
 476 concordance with human judgments. In addition, we introduce MedInsightAgent, a multi-agent
 477 framework that integrates multiple data-acquisition modules, analysis components, and external
 478 tools specifically designed for mining insights from medical images. Experimental results show
 479 that MedInsightBench exposes many key challenges in medical-insight discovery and that MedIn-
 480 sightAgent effectively improves the performance of several LMMs. In future work, we will further
 481 refine the multi-agent framework to improve its performance in insight discovery, thereby contribut-
 482 ing to significant advances in medical insight research.

486 REFERENCES
487

488 Shuai Bai, Keqin Chen, Xuejing Liu, Jialin Wang, Wenbin Ge, Sibo Song, Kai Dang, Peng Wang,
489 Shijie Wang, Jun Tang, Humen Zhong, Yuanzhi Zhu, Mingkun Yang, Zhaohai Li, Jianqiang Wan,
490 Pengfei Wang, Wei Ding, Zheren Fu, Yiheng Xu, Jiabo Ye, Xi Zhang, Tianbao Xie, Zesen Cheng,
491 Hang Zhang, Zhibo Yang, Haiyang Xu, and Junyang Lin. Qwen2.5-vl technical report. *arXiv*
492 preprint *arXiv:2502.13923*, 2025.

493 Nan Chen, Yuge Zhang, Jiahang Xu, Kan Ren, and Yuqing Yang. Viseval: A benchmark for data
494 visualization in the era of large language models. *IEEE Transactions on Visualization and Com-*
495 *puter Graphics*, 2024a.

496 Qiuhibi Chen, Xuancheng Yao, Huping Ye, and Yi Hong. Enhancing 3d medical image un-
497 derstanding with pretraining aided by 2d multimodal large language models. *arXiv preprint*
498 *arXiv:2509.09064*, 2025.

499

500 Zhe Chen, Jiannan Wu, Wenhui Wang, Weijie Su, Guo Chen, Sen Xing, Muyan Zhong, Qinglong
501 Zhang, Xizhou Zhu, Lewei Lu, et al. Internvl: Scaling up vision foundation models and aligning
502 for generic visual-linguistic tasks. In *Proceedings of the IEEE/CVF Conference on Computer*
503 *Vision and Pattern Recognition*, pp. 24185–24198, 2024b.

504 Mingwen Dong, Nischal Ashok Kumar, Yiqun Hu, Anuj Chauhan, Chung-Wei Hang, Shuaichen
505 Chang, Lin Pan, Wuwei Lan, Henghui Zhu, Jiarong Jiang, et al. Practiq: A practical conversa-
506 tional text-to-sql dataset with ambiguous and unanswerable queries. In *Proceedings of the 2025*
507 *Conference of the Nations of the Americas Chapter of the Association for Computational Lin-
508 guistics: Human Language Technologies (Volume 1: Long Papers)*, pp. 255–273, 2025.

509 Zhihao Fan, Lai Wei, Jialong Tang, Wei Chen, Wang Siyuan, Zhongyu Wei, and Fei Huang. AI
510 hospital: Benchmarking large language models in a multi-agent medical interaction simulator. In
511 Owen Rambow, Leo Wanner, Marianna Apidianaki, Hend Al-Khalifa, Barbara Di Eugenio, and
512 Steven Schockaert (eds.), *Proceedings of the 31st International Conference on Computational*
513 *Linguistics*, pp. 10183–10213, Abu Dhabi, UAE, January 2025. Association for Computational
514 Linguistics. URL <https://aclanthology.org/2025.coling-main.680/>.

515

516 Xueyu Hu, Ziyu Zhao, Shuang Wei, Ziwei Chai, Qianli Ma, Guoyin Wang, Xuwu Wang, Jing Su,
517 Jingjing Xu, Ming Zhu, et al. Infiagent-dabench: evaluating agents on data analysis tasks. In
518 *Proceedings of the 41st International Conference on Machine Learning*, pp. 19544–19572, 2024.

519 Yixing Jiang, Kameron C Black, Gloria Geng, Danny Park, James Zou, Andrew Y Ng, and
520 Jonathan H Chen. Medagentbench: A realistic virtual ehr environment to benchmark medical
521 llm agents. *arXiv preprint arXiv:2501.14654*, 2025.

522 Gyubok Lee, Hyeonji Hwang, Seongsu Bae, Yeonsu Kwon, Woncheol Shin, Seongjun Yang, Min-
523 joon Seo, Jong-Yeup Kim, and Edward Choi. Ehrsql: A practical text-to-sql benchmark for
524 electronic health records. *Advances in Neural Information Processing Systems*, 35:15589–15601,
525 2022.

526

527 Fangyu Lei, Jixuan Chen, Yuxiao Ye, Ruisheng Cao, Dongchan Shin, Hongjin SU, ZHAOQING
528 SUO, Hongcheng Gao, Wenjing Hu, Pengcheng Yin, et al. Spider 2.0: Evaluating language mod-
529 els on real-world enterprise text-to-sql workflows. In *The Thirteenth International Conference on*
530 *Learning Representations*, 2024.

531 Chin-Yew Lin. Rouge: A package for automatic evaluation of summaries. In *Text summarization*
532 *branches out*, pp. 74–81, 2004.

533

534 Jie Liu, Wenxuan Wang, Zizhan Ma, Guolin Huang, Yihang SU, Kao-Jung Chang, Wenting Chen,
535 Haoliang Li, Linlin Shen, and Michael Lyu. Medchain: Bridging the gap between llm agents and
536 clinical practice through interactive sequential benchmarking. *arXiv preprint arXiv:2412.01605*,
537 2024.

538 Yang Liu, Dan Iter, Yichong Xu, Shuohang Wang, Ruochen Xu, and Chenguang Zhu. G-eval: NLG
539 evaluation using gpt-4 with better human alignment. In Houda Bouamor, Juan Pino, and Kali-
ka Bali (eds.), *Proceedings of the 2023 Conference on Empirical Methods in Natural Language*

540 *Processing*, pp. 2511–2522, Singapore, December 2023. Association for Computational Linguistics.
 541 doi: 10.18653/v1/2023.emnlp-main.153. URL <https://aclanthology.org/2023.emnlp-main.153/>.

542

543 Ming Y Lu, Bowen Chen, Drew FK Williamson, Richard J Chen, Melissa Zhao, Aaron K Chow,
 544 Kenji Ikemura, Ahrong Kim, Dimitra Pouli, Ankush Patel, et al. A multimodal generative ai
 545 copilot for human pathology. *Nature*, 634(8033):466–473, 2024.

546

547 Pingchuan Ma, Rui Ding, Shuai Wang, Shi Han, and Dongmei Zhang. InsightPilot: An LLM-
 548 empowered automated data exploration system. In Yansong Feng and Els Lefever (eds.), *Pro-
 549 ceedings of the 2023 Conference on Empirical Methods in Natural Language Processing: Sys-
 550 tem Demonstrations*, pp. 346–352, Singapore, December 2023. Association for Computational
 551 Linguistics. doi: 10.18653/v1/2023.emnlp-demo.31. URL <https://aclanthology.org/2023.emnlp-demo.31/>.

552

553

554 Rafael Mendoza, Noah Kim, Isabella Cruz, Priya Singh, Sofia Patel, and Aria Martinez. Advance-
 555 ments in multimodal medical data processing for improved disease diagnosis.

556

557 OpenAI. Gpt-4o system card, 2024. URL <https://arxiv.org/abs/2410.21276>.

558

559 OpenAI. Gpt-5 system card. 2025. URL <https://cdn.openai.com/gpt-5-system-card.pdf>.

560

561 Geliang Ouyang, Jingyao Chen, Zhihe Nie, Yi Gui, Yao Wan, Hongyu Zhang, and Dongping Chen.
 562 nvAgent: Automated data visualization from natural language via collaborative agent workflow.
 563 In Wanxiang Che, Joyce Nabende, Ekaterina Shutova, and Mohammad Taher Pilehvar (eds.), *Pro-
 564 ceedings of the 63rd Annual Meeting of the Association for Computational Linguistics (Volume 1:
 565 Long Papers)*, pp. 19534–19567, July 2025. URL <https://aclanthology.org/2025.acl-long.960/>.

566

567 Shrey Pandit, Jiawei Xu, Junyuan Hong, Zhangyang Wang, Tianlong Chen, Kaidi Xu, and Ying
 568 Ding. Medhallu: A comprehensive benchmark for detecting medical hallucinations in large lan-
 569 guage models. *arXiv preprint arXiv:2502.14302*, 2025.

570

571 Alberto Sánchez Pérez, Alaa Boukhary, Paolo Papotti, Luis Castejón Lozano, and Adam Elwood. An
 572 llm-based approach for insight generation in data analysis. In *Proceedings of the 2025 Conference
 573 of the Nations of the Americas Chapter of the Association for Computational Linguistics: Human
 574 Language Technologies (Volume 1: Long Papers)*, pp. 562–582, 2025.

575

576 Gaurav Sahu, Abhay Puri, Juan A Rodriguez, Amirhossein Abaskohi, Mohammad Chegini, Alexan-
 577 dre Drouin, Perouz Taslakian, Valentina Zantedeschi, Alexandre Lacoste, David Vazquez, et al.
 578 Insightbench: Evaluating business analytics agents through multi-step insight generation. In *The
 579 Thirteenth International Conference on Learning Representations*, 2025.

580

581 Samuel Schmidgall, Rojin Ziae, Carl Harris, Eduardo Reis, Jeffrey Jopling, and Michael Moor.
 582 Agentclinic: a multimodal agent benchmark to evaluate ai in simulated clinical environments.
 583 *arXiv preprint arXiv:2405.07960*, 2024.

584

585 Fangxin Shang, Yuan Xia, Dalu Yang, Yahui Wang, and Binglin Yang. Medrepbench: A com-
 586 prehensive benchmark for medical report interpretation. *arXiv preprint arXiv:2508.16674*, 2025.

587

588 Andries Smit, Paul Duckworth, Nathan Grinsztajn, Kale ab Tessera, Thomas Barrett, and Arnu
 589 Pretorius. Are we going MAD? benchmarking multi-agent debate between language models for
 590 medical q&a. In *Deep Generative Models for Health Workshop NeurIPS 2023*, 2023. URL
 591 <https://openreview.net/forum?id=Bfr0m4Ucl6>.

592

593 Kai Sun, Siyan Xue, Fuchun Sun, Haoran Sun, Yu Luo, Ling Wang, Siyuan Wang, Na Guo, Lei
 594 Liu, Tian Zhao, et al. Medical multimodal foundation models in clinical diagnosis and treatment:
 595 Applications, challenges, and future directions. *Artificial Intelligence in Medicine*, pp. 103265,
 596 2025a.

594 Yuxuan Sun, Yunlong Zhang, Yixuan Si, Chenglu Zhu, Kai Zhang, Zhongyi Shui, Jingxiong Li,
 595 Xuan Gong, XINHENG LYU, Tao Lin, and Lin Yang. Pathgen-1.6m: 1.6 million pathology
 596 image-text pairs generation through multi-agent collaboration. In *The Thirteenth Interna-*
 597 *tional Conference on Learning Representations*, 2025b. URL [https://openreview.net/](https://openreview.net/forum?id=rFpZnn11gj)
 598 [forum?id=rFpZnn11gj](https://openreview.net/forum?id=rFpZnn11gj).

599 Ivan Sviridov, Amina Miftakhova, Artemiy Tereshchenko, Galina Zubkova, Pavel Blinov, and
 600 Andrey Savchenko. 3mdbench: Medical multimodal multi-agent dialogue benchmark. *arXiv*
 601 *preprint arXiv:2504.13861*, 2025.

602

603 Xiangru Tang, Daniel Shao, Jiwoong Sohn, Jiapeng Chen, Jiayi Zhang, Jinyu Xiang, Fang Wu,
 604 Yilun Zhao, Chenglin Wu, Wenqi Shi, et al. Medagentsbench: Benchmarking thinking models
 605 and agent frameworks for complex medical reasoning. *arXiv preprint arXiv:2503.07459*, 2025.

606

607 Xidong Wang, Guiming Chen, Song Dingjie, Zhang Zhiyi, Zhihong Chen, Qingying Xiao, Junying
 608 Chen, Feng Jiang, Jianquan Li, Xiang Wan, Benyou Wang, and Haizhou Li. CMB: A comprehen-
 609 sive medical benchmark in Chinese. In Kevin Duh, Helena Gomez, and Steven Bethard (eds.),
 610 *Proceedings of the 2024 Conference of the North American Chapter of the Association for Com-
 611 putational Linguistics: Human Language Technologies (Volume 1: Long Papers)*, pp. 6184–6205,
 612 Mexico City, Mexico, June 2024. Association for Computational Linguistics. doi: 10.18653/v1/
 613 2024.naacl-long.343. URL <https://aclanthology.org/2024.naacl-long.343/>.

614

615 Luoxuan Weng, Xingbo Wang, Junyu Lu, Yingchaojie Feng, Yihan Liu, Haozhe Feng, Danqing
 616 Huang, and Wei Chen. Insightlens: Augmenting llm-powered data analysis with interactive in-
 617 sight management and navigation. *IEEE Transactions on Visualization and Computer Graphics*,
 618 2025.

619

620 Kevin Wu, Eric Wu, Rahul Thapa, Kevin Wei, Angela Zhang, Arvind Suresh, Jacqueline J Tao,
 621 Min Woo Sun, Alejandro Lozano, and James Zou. Medcasereasoning: Evaluating and learning
 622 diagnostic reasoning from clinical case reports. *arXiv preprint arXiv:2505.11733*, 2025.

623

624 Zhiyu Wu, Xiaokang Chen, Zizheng Pan, Xingchao Liu, Wen Liu, Damai Dai, Huazuo Gao, Yiyang
 625 Ma, Chengyue Wu, Bingxuan Wang, et al. Deepseek-vl2: Mixture-of-experts vision-language
 626 models for advanced multimodal understanding. *arXiv preprint arXiv:2412.10302*, 2024.

627

628 Peng Xia, Jinglu Wang, Yibo Peng, Kaide Zeng, Xian Wu, Xiangru Tang, Hongtu Zhu, Yun Li,
 629 Shujie Liu, Yan Lu, et al. Mmedagent-rl: Optimizing multi-agent collaboration for multimodal
 630 medical reasoning. *arXiv preprint arXiv:2506.00555*, 2025.

631

632 Wenyi Xu, Yuren Mao, Xiaolu Zhang, Chao Zhang, Xuemei Dong, Mengfei Zhang, and Yunjun
 633 Gao. Dagent: A relational database-driven data analysis report generation agent. *arXiv preprint*
 634 *arXiv:2503.13269*, 2025.

635

636 Xi Xu, Jianqiang Li, Zhichao Zhu, Linna Zhao, Huina Wang, Changwei Song, Yining Chen, Qing
 637 Zhao, Jijiang Yang, and Yan Pei. A comprehensive review on synergy of multi-modal data and ai
 638 technologies in medical diagnosis. *Bioengineering*, 11(3):219, 2024.

639

640 Zhiyu Yang, Zihan Zhou, Shuo Wang, Xin Cong, Xu Han, Yukun Yan, Zhenghao Liu, Zhixing
 641 Tan, Pengyuan Liu, Dong Yu, Zhiyuan Liu, Xiaodong Shi, and Maosong Sun. MatPlotAgent:
 642 Method and evaluation for LLM-based agentic scientific data visualization. In Lun-Wei Ku, Andre
 643 Martins, and Vivek Srikumar (eds.), *Findings of the Association for Computational Linguistics:
 644 ACL 2024*, pp. 11789–11804, Bangkok, Thailand, August 2024. Association for Computational
 645 Linguistics. doi: 10.18653/v1/2024.findings-acl.701. URL [https://aclanthology.org/](https://aclanthology.org/2024.findings-acl.701/)
 646 [2024.findings-acl.701/](https://aclanthology.org/2024.findings-acl.701/).

647

648 Shunyu Yao, Jeffrey Zhao, Dian Yu, Nan Du, Izhak Shafran, Karthik Narasimhan, and Yuan Cao.
 649 React: Synergizing reasoning and acting in language models. In *International Conference on*
 650 *Learning Representations (ICLR)*, 2023.

651

652 Zaifu Zhan, Shuang Zhou, Xiaoshan Zhou, Yongkang Xiao, Jun Wang, Jiawen Deng, He Zhu,
 653 Yu Hou, and Rui Zhang. Retrieval-augmented in-context learning for multimodal large language
 654 models in disease classification. *arXiv preprint arXiv:2505.02087*, 2025.

648 Chao Zhang, Yuren Mao, Yijiang Fan, Yu Mi, Yunjun Gao, Lu Chen, Dongfang Lou, and Jinshu Lin.
649 Fysql: Model-agnostic llms-based text-to-sql framework for financial analysis. In *Companion of*
650 *the 2024 International Conference on Management of Data*, pp. 93–105, 2024.

651
652 Yaoming Zhu, Sidi Lu, Lei Zheng, Jiaxian Guo, Weinan Zhang, Jun Wang, and Yong Yu. Texxygen:
653 A benchmarking platform for text generation models. In *The 41st international ACM SIGIR*
654 *conference on research & development in information retrieval*, pp. 1097–1100, 2018.

655 Yinghao Zhu, Ziyi He, Haoran Hu, Xiaochen Zheng, Xichen Zhang, Zixiang Wang, Junyi Gao,
656 Liantao Ma, and Lequan Yu. Medagentboard: Benchmarking multi-agent collaboration with
657 conventional methods for diverse medical tasks. *arXiv preprint arXiv:2505.12371*, 2025.


658
659 Yuxin Zuo, Shang Qu, Yifei Li, Zhang-Ren Chen, Xuekai Zhu, Ermo Hua, Kaiyan Zhang, Ning
660 Ding, and Bowen Zhou. MedxpertQA: Benchmarking expert-level medical reasoning and un-
661 derstanding. In *Forty-second International Conference on Machine Learning*, 2025. URL
662 <https://openreview.net/forum?id=IyVcxU0RKI>.

663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701


702 A DATASET ANALYSIS 703

704 A.1 DETAILED STATISTIC OF MEDINSIGHTBENCH 705

706 Figure 3 and Figure 4 present detailed statistical information on MedInsightBench, including the
707 distribution of different Insight categories, the average number of tokens in Questions and Insights
708 per category, and the distribution across difficulty levels.



721 Figure 3: The distribution of different Insight
722 Types in MedInsightBench and the average token
723 count of Question and Insight in each type
724 of data.



721 Figure 4: The distribution of different difficulty
722 level in MedInsightBench.

726 A.2 INSIGHT TYPES 727

728 In this paper, we provide a comprehensive interpretation of data insights by six insight categories.
729 A detailed description of each insight category is provided below:

- 731 • **Descriptive:** In the medical context, descriptive insights summarize what has already occurred by aggregating and visualizing historical clinical and operational data. For example, charts of monthly inpatient admissions by diagnosis, trends in laboratory test volumes, or distributions of medication use between departments, so clinicians and administrators can quickly understand the current and past state of patients and services.
- 732 • **Diagnostic:** Diagnostic insights explain why the observed clinical or operational patterns occurred by identifying correlations, temporal associations, and plausible causal factors, such as linking a rise in postoperative infections to a change in sterilization procedures, a particular implant type, or changes in staffing, helping teams prioritize investigations and corrective actions.
- 733 • **Predictive:** Predictive insights use historical patient records, longitudinal vitals, laboratory trajectories, imaging characteristics, and social determinants to forecast future outcomes or events, such as 30-day readmission risk, likelihood of ICU transfer, or expected lab deterioration, providing probabilities and confidence estimates to inform proactive clinical planning.
- 734 • **Prescriptive:** Prescriptive insights translate predictions and diagnostics into concrete, actionable recommendations that balance benefits, risks, and constraints, for example, suggesting personalized treatment adjustments, targeted follow-up schedules, or resource allocation strategies (e.g., bed assignment or staffing changes) designed to improve results or operational efficiency.
- 735 • **Evaluative:** Evaluative insights assess the quality, reliability, and limitations of the data and analyze themselves by auditing data completeness, bias, model calibration, and external validity, for example, reporting subgroup performance disparities of a mortality model or highlighting key missing variables that undermine the conclusions.
- 736 • **Exploratory:** Exploratory insights search for unknown or unexpected patterns without a prior hypothesis, using techniques such as clustering, anomaly detection, and dimensional-

756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 ity reduction to uncover new patient subgroups, unusual temporal events, or latent relationships, such as discovering a previously unrecognized phenotype associated with distinct biomarker patterns that merits further clinical study.

A.3 EXAMPLES OF MEDINSIGHTBENCH

Tables 6 and 7 present Case 4 from MedInsightBench, which includes a specific goal, image of medical cancer pathology, and a series of insights. Each insight consists of a question, an insight text, and an insight type.

Goal	Correlate histopathologic features of the tongue carcinoma with staging parameters, margin status, nodal metastasis, and HPV status to guide prognostic assessment and treatment planning.
Pathological Image	

Table 6: Goal and pathological image of Case 4 in MedInsightBench.

B DETAILS OF EVALUATION FRAMEWORK

At present, evaluation of insights is primarily based on automated text match metrics and G-Eval scoring. In InsightBench, it depends exclusively on LLAMA-3-Eval as the evaluator, thereby risking by model’s inherent biases. Moreover, the evaluation merely measures how many ground-truth insight is matched by predicted insights while neglecting the generated erroneous insights. Lastly, it concentrates solely on discovering pre-annotated insights and does not recognize or reward the discovery of novel insights. Therefore, to address these shortcomings, we need to propose a set of revised evaluation criteria and design novel metrics accordingly.

Evaluating the medical insight discovery capabilities of the LMM and the Agent on MedInsightBench requires comparing the generated insights (I) with the annotated ground-truth insights (GT). To enable a more comprehensive and rigorous evaluation that accurately reflects analytical ability, we propose a novel automated evaluation framework that employs four principal measures: recall, precision, $F1$, and novelty. In the following, we detail each component of our four methodologies.

B.1 INSIGHTS RECALL EVALUATION

To assess if ground-truth insights are discovered, we need to calculate the recall rate by adapting the iterative matching protocol. We count the scores between each ground-truth insight ($gt \in GT$) and each generated insight ($i \in I$). Then we record the highest-scoring counterpart based on each ground-truth insight (gt) and calculate the expectation score (E) as the final output. The formula for recall evaluation is shown as in equation 4, with S representing the evaluator, such as ROUGE-1 or G-Eval.

$$\text{Score}_{\text{recall}}(S) = E_{gt \sim \text{Unif}(GT)} \left[\max_{i \in I} S(gt, i) \right] \quad (4)$$

810	Insights Details
811	Question 1: What is the diagnosis, location, size, and depth of invasion as documented in the pathology report for the excised tongue specimen?
812	Insight 1: Invasive keratinizing squamous cell carcinoma identified in the right lateral tongue dorsum and lateral tongue, approximately 2.0 cm in greatest dimension with muscle invasion.
813	Type 1: Diagnostic
814	Question 2: Does the pathology report confirm the presence of metastatic carcinoma in a lymph node from the right neck level 2, and what is the greatest dimension measurement of the identified tumor deposit?
815	Insight 2: Metastatic carcinoma identified in one lymph node from right neck level 2 with a tumor deposit measuring 1.9 cm.
816	Type 2: Diagnostic
817	Question 3: What is the status of all surgical margins regarding tumor presence in the final pathology report?
818	Insight 3: Final surgical margins are negative for tumor in all specimens.
819	Type 3: Descriptive
820	Question 4: What are the specific pathologic stage descriptors for the primary tumor, regional lymph nodes, and the number of lymph nodes examined versus involved as documented in the report?
821	Insight 4: Pathologic staging is pT1 pN1 with 44 lymph nodes examined and 1 involved.
822	Type 4: Descriptive
823	Question 5: What are the reported findings regarding histologic grade, extracapsular extension, perineural invasion, and bony/cartilage invasion?
824	Insight 5: Tumor is moderately-differentiated squamous cell carcinoma without extracapsular extension, perineural invasion, or bony/cartilage invasion.
825	Type 5: Descriptive
826	Question 6: What were the results of HPV testing for both p16 immunohistochemistry and high risk HPV in situ hybridization?
827	Insight 6: HPV testing performed shows p16 negative by immunohistochemistry and high risk HPV negative by in situ hybridization.
828	Type 6: Descriptive
829	Question 7: Does the pathology report indicate both the number of lymph nodes involved by metastatic carcinoma and the total number examined, along with the presence or absence of extracapsular extension?
830	Insight 7: Single lymph node metastasis (1/44) without extracapsular extension suggests intermediate recurrence risk; consider adjuvant therapy based on multidisciplinary discussion.
831	Type 7: Predictive
832	Question 8: Does the pathology report confirm that all intraoperative frozen section consultations for mucosal margins were benign, indicating adequate surgical clearance?
833	Insight 8: All intraoperative frozen section consultations for mucosal margins were benign, confirming adequate surgical clearance.
834	Type 8: Evaluative
835	Question 9: What are the specific benign findings and lymph node levels documented as negative for tumor in the report?
836	Insight 9: Additional benign findings include minor salivary gland tissue and multiple lymph node levels negative for tumor.
837	Type 9: Descriptive
838	Question 10: What is the HPV status of the oral cavity squamous cell carcinoma as determined by testing documented in the report?
839	Insight 10: HPV-negative status in an oral cavity squamous cell carcinoma suggests non-HPV driven etiology; consider additional molecular profiling for treatment guidance.
840	Type 10: Exploratory

Table 7: Insight details of Case 4 in MedInsightBench.

B.2 INSIGHTS PRECISION EVALUATION

Only focusing on the recall rate may overlook the possibility that agents generate irrelevant or unnecessary insights. To address this limitation, it is essential to further evaluate the accuracy of each generated insight to enhance the overall evaluation system. Similarly, we also enumerate the scores between the ground-truth and the generated insight. However, to calculate the precision rate, we

864 need to record the highest score based on each generated insight (I). The formula for precision
 865 evaluation is presented as in Equation 5.
 866

$$\text{Score}_{\text{precision}}(\mathcal{S}) = E_{i \sim \text{Unif}(I)} \left[\max_{gt \in GT} \mathcal{S}(i, gt) \right] \quad (5)$$

870 B.3 INSIGHTS $F1$ EVALUATION 871

872 To comprehensively assess the capability of insight discovery, we proposed a new measurement
 873 called insight $F1$ score. With the insight recall score and the insight precision score, we can calculate
 874 the insight $F1$ score through the formula in Equation 6.
 875

$$\text{Score}_{F1}(\mathcal{S}) = \frac{2 * \text{Score}_{\text{recall}}(\mathcal{S}) * \text{Score}_{\text{precision}}(\mathcal{S})}{\text{Score}_{\text{recall}}(\mathcal{S}) + \text{Score}_{\text{precision}}(\mathcal{S})} \quad (6)$$

879 B.4 INSIGHTS NOVELTY EVALUATION 880

881 Given the limitations of merely aligning with ground-truth insights, it is essential to evaluate the
 882 capacity of discovering novel insights. We identify insights with a G-Eval score greater than 5 in
 883 the insight precision evaluation as correct, while the other insights are classified as incorrect and
 884 subjected to a secondary evaluation focused on innovation. During the evaluation, we utilize three
 885 distinct LMMs to mitigate bias. The insight can be labeled as a potential novel insight when at
 886 least two models judge it as correct. To obtain more accurate judgments, we provide LMMs with
 887 multi-modal information, including the goal, the medical image, and historical insights, and use a
 888 Chain-of-Thought (CoT) reasoning framework. The formula for novelty evaluation is expressed as
 889 in Equation 7, where $\text{LMM}_j(i) \in \{0, 1\}$, $\delta \in \{0, 1\}$, j is the number of LMMs, $\mathbf{1}$ means indicator
 890 function, M and N indicate the number of correct and incorrect insights in precision evaluation,
 891 respectively.
 892

$$\text{Score}_{\text{novelty}} = \frac{M + \delta \sum_{i=1}^N \mathbf{1}\left(\sum_{j=1}^3 \text{LMM}_j(i) \geq 2\right)}{N + M} \quad (7)$$

893 When $\delta = 1$, the formula calculates the Innovation score. For comparison, we set $\delta = 0$ to obtain
 894 the Original score during the evaluation.
 895

900 C DETAILS OF HUMAN ANNOTATION 901

902 Regarding annotators, our primary labelers were students with medical training. To enhance the re-
 903 liability of the annotation process, we further conducted inter-annotator agreement analyses. Speci-
 904 fically, we collected each annotator’s judgments from the dataset quality checks as well as their scor-
 905 ing of model outputs across all baselines, and computed several agreement metrics. The average
 906 Intraclass Correlation Coefficient (ICC) across raters was approximately 0.82, and Krippendorff’s
 907 α was around 0.84. We additionally computed the Pearson correlation coefficient, which was about
 908 0.76. Taken together, these results indicate that our annotators exhibit high reliability and strong
 909 consistency across individuals.
 910


911 Regarding annotation details, our work includes two major components that required substantial
 912 manual annotation:

- 913 1. **Quality assessment of the benchmark dataset.** In Section 3.4, we describe in detail the metrics
 914 and procedures used for dataset quality evaluation. Each annotator reviewed the original report
 915 corresponding to each sample and performed a binary (0–1) correctness judgment on the data
 916 item or on each question/insight derived from it. The evaluation criteria included logical and
 917 medical soundness, consistency with image evidence, and alignment between the report and the
 918 ground-truth annotations.

918
 919
 920
 921
 922
 923
 924
 925
 926
 927 2. **Human scoring of benchmark results.** In several experiments presented in Appendix C, we
 928 employed human experts to provide annotation-based scoring to assess the validity and reliability
 929 of our evaluation metrics. Similar to the scoring mechanism used in G-Eval, human annotators
 930 compared model- or agent-generated insights against the ground-truth insights based on semantic
 931 similarity, and rated aspects such as accuracy and plausibility on a 1–10 scale.
 932

D MORE EXPERIMENT RESULTS IN DIFFERENT INSIGHT TYPE

927 **Insight F_1 Score Provides a Better Reflection of Insight Capabilities.** To deepen the analysis,
 928 we also collected expert human scores and compared Insight Recall with Insight F_1 , which is shown
 929 in Figure 5. In particular, Insight F_1 values exceed the corresponding Insight Recall scores and
 930 lie closer to human evaluations. This pattern suggests that Insight F_1 is a more effective proxy for
 931 measuring medical-insight discovery capability and better reflects human judgment.
 932



949 Figure 5: Comparison of G-Eval scores in Insight Recall and Insight F_1 , and Expert Scores in
 950 Human Evaluation.
 951
 952
 953

954 **Effective scheduling and orchestration of multi-agent frameworks can yield significant perfor-
 955 mance improvements and enhanced system efficiency.** To complete the experimental compar-
 956 ison, we augmented the ReAct framework with the same three tools used by MedInsightAgent and
 957 evaluated its performance, which results are presented in Table 8. As shown, when provided with
 958 the same tools, ReAct indeed achieves a clear performance gain relative to the earlier setup that
 959 used only the computation module and web-search tool. However, it still falls slightly short of our
 960 proposed MedInsightAgent. This indicates that MedInsightAgent’s advantage is not merely due to
 961 the use of powerful tools, but also reflects the effectiveness of the agentic orchestration mechanism
 962 we introduced.
 963

Baselines	Insights Recall		Insights Precision		Insights F_1		Insights Novelty	
	ROUGE-1	G-Eval	ROUGE-1	G-Eval	ROUGE-1	G-Eval	Original	Innovation
MedInsightAgent (GPT-4o)	0.189	0.361	0.197	0.413	0.193	0.384	0.180	0.270
ReAct (GPT-4o) with the same tools	0.181	0.302	0.203	0.371	0.192	0.332	0.142	0.224
	0.187	0.349	0.205	0.397	0.196	0.371	0.171	0.256

968 Table 8: Comparison of Insight discovery performance in agents with the same tools on MedInsight-
 969 Bench.
 970

972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025		
	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025
973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025
973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025	973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025

Table 9: Comparison of evaluation scores in Novelty metrics between model-generated and human-assessed.

The Novelty metric effectively reflects an agent’s ability to uncover new medical insights. To further enhance the validity and reliability of our Novelty metric, we conducted an additional round of manual inspection and sampled scoring of the model-generated insights to assess whether they contained genuine medical findings. We then compared these human-annotated scores with the automatically computed novelty scores, as shown in Table 9. We observe that the model outputs do exhibit a certain degree of misjudgment or overestimation. Nevertheless, the human-verified novelty scores still show a consistent improvement, indicating that our MedInsightAgent framework can provide discoveries that are more insightful.

E ALGORITHM OF MEDINSIGHTAGENT

The general algorithm framework of MedInsightAgent is shown in the Algorithm 1.

1026 **Algorithm 1** Overall Multi-Agent Insight Mining Framework

1027 **Require:** Medical image I , Analysis goal G

1028 **Ensure:** Final insights S , Answers A , Root questions Q , Follow-up questions T

1029 1: **Initialize:** $F, K, D, Q, A, S, T \leftarrow \emptyset$

1030 **Stage 1: Visual Root Finder (VRF)** (Eq. 1)

1031 2: Extract initial visual summary and keywords using Image-Summarization Module:

1032
$$(F, K) = \mathcal{IS}_M(I)$$

1033 3: Retrieve external domain knowledge based on keywords:

1034
$$D = \mathcal{WR}_M(K)$$

1035 4: Generate initial set of root questions by combining I, G, F , and D :

1036
$$Q = \mathcal{L}(I, G, F, D)$$

1037 **Stage 2: Analytical Insight Agent (AIA)** (Eq. 2)

1038 5: **for** each root question $q_i \in Q$ **do**

1039 6: Extract question-specific image evidence:

1040
$$E_i = \mathcal{LAT}(I, q_i)$$

1041 7: Generate answer and corresponding insight:

1042
$$(a_i, s_i) = \mathcal{G}(q_i, I, E_i)$$

1043 8: **end for**

1044 9: Collect all answers and insights:

1045
$$A = \{a_i\}_{i=1}^m, \quad S = \{s_i\}_{i=1}^m$$

1046 **Stage 3: Follow-up Question Composer (FQC)** (Eq. 3)

1047 10: Generate n candidate follow-up questions for each root question:

1048
$$C = \mathcal{F}(I, G, A, F, D, Q)$$

1049 11: Select the best follow-up question c_{best} using a scoring function \mathcal{S} :

1050
$$c_{\text{best}} = \mathcal{S}(C)$$

1051 12: Update follow-up question set:

1052
$$T = T \cup \{c_{\text{best}}\}$$

1053 **Iteration:**

1054 13: **while** stopping criterion not met **do**

1055 14: Pass c_{best} back to Stage 2 (AIA) for deeper analysis

1056 15: Update A, S , and Q with new findings

1057 16: **end while**

1058 17: **return** Final sets (S, A, Q, T)

1069 **F PROMPTS**

1071 **Prompts in Data Construction Pipeline of MedInsightBench.** Prompt 1, Prompt 2, Prompt 3
 1072 and Prompt 4 present the detailed prompts for data construction in MedInsightBench.

1074 **Prompt 1: Prompt for the Pathological Report Verification.**

1075 1 Given the following cancer pathology report text:
 1076 2 **<report>{report_text}</report>**
 1077 3
 1078 4 Instructions:
 1079 5 * Analyze the given cancer pathology report text (OCR output from a
 → PDF). Perform these checks:

```

1080 6 Critical checks (must pass for the report to be usable for automated
1081 7 → data-insight extraction):
1082 8 1. Final Diagnosis / Impression present and unambiguous (parsable
1083 9 → diagnostic phrase).
1084 10 2. Tumor size(s) present with numeric value(s) and units (e.g., "2.3
1085 11 → cm", "10 mm") or explicit statement that size not applicable.
1086 12 3. Tumor grade or stage info present when relevant to the specimen
1087 13 → type (or explicit "not applicable").
1088 14 4. Lymph node status present and parsable (e.g., "0/12 nodes", "3/5
1089 15 → positive").
1090 16 5. Margin status present and parsable (clear:
1091 17 → positive/negative/closest margin and measurement if given).
1092 18 6. Specimen/site and laterality clearly stated (e.g., "left lung,
1093 19 → lower lobe").
1094 20 7. Text quality/linkability: OCR not heavily garbled (no pervasive
1095 21 → garbage characters), and at least one linking identifier is
1096 22 → present (accession number, specimen ID, slide ID) OR the report
1097 23 → contains fully parsable structured key-values that allow
1098 24 → unambiguous extraction.

1099 25 Additional helpful checks (not strictly required but increase
1100 26 → usability):
1101 27 8. IHC / molecular results present and include marker names with
1102 28 → interpretation (e.g., "ER: positive 90%") if performed.
1103 29 9. Clinical history/indication present (useful for context).
1104 30 10. No internal contradictions (e.g., both "benign" and "invasive
1105 31 → carcinoma" without explanation).
1106 32 11. Negation correctly captured for critical phrases (e.g., "no
1107 33 → lymphovascular invasion", "negative for malignancy").

1108 34 * Decision rule:
1109 35   - If ALL Critical checks (1 to 7) pass, output 1. Otherwise, output
1110 36   → 0.
1111 37   - NOTE: If critical checks pass but any Additional check fails,
1112 38   → still output 1 but mention the missing helpful items in the reason.

1113 39 * Output format requirements (strict):
1114 40   - Your decision must be strictly enclosed in '<decision></decision>'
1115 41   → tags and be either '1' or '0'.
1116 42   - Give your reason inside '<reason></reason>'. The reason must be
1117 43   → concise (max ~120 words), and must include:
1118 44     - which critical checks passed/failed (brief labels, e.g.,
1119 45     → "C1:PASS; C2:FAIL"),
1120 46     - the top 1 to 2 specific problems found (if any), and
1121 47     - a short recommended action (one of: "re-OCR", "manual
1122 48     → pathologist review", "link accession IDs", "proceed with
1123 49     → spot-checks").
1124 50   - Your final reply must contain only these two tags and nothing else.

1125 51 Refer to the example responses below.
1126 52 Example (acceptable):
1127 53 <decision>1</decision>
1128 54 <reason>PASS. Critical checks: C1,C2,C3,C4,C5,C6,C7 PASS. IHC missing
1129 55   → (A8). Text parsable with accession present. Recommend proceeding
1130 56   → with spot-checks and include IHC curation if available.</reason>
```

1127 57 Example (unacceptable):
1128 58 **<decision>0</decision>**
1129 59 **<reason>FAIL. Critical checks failed: C2 (tumor size missing), C7 (OCR**
1130 60 → **garbling: many non-printable chars).** Recommend re-running OCR with
1131 61 → **an alternate engine and manual pathologist review for affected**
1132 62 → **samples.**</reason>

Prompt 2: Prompt for the Insights Generation.

```

1134
1135 1 Given the following cancer pathology report text:
1136 2 <report>{report_text}</report>
1137 3
1138 4 Given the following report evidence:
1139 5 <evidence>{evidence_text}</evidence>
1140 6
1141 7 Instructions:
1142 8 * You will analyze the given cancer pathology report (OCR output that
1143 9   ↳ has passed prior usability checks) and evidence. Then extract ALL
1144 10  ↳ pathology data insights present in the report. The number of
1145 11  ↳ insights may vary by report; list every distinct insight you can
1146 12  ↳ infer from the text.
1147 13
1148 14 * Insight categories (choose one per insight):
1149 15   - Descriptive: factual summaries of what the report states (e.g.,
1150 16     ↳ specimen type, tumor size, node count, IHC results).
1151 17   - Diagnostic: statements that identify disease or etiology (e.g.,
1152 18     ↳ "invasive ductal carcinoma", "metastatic adenocarcinoma").
1153 19   - Predictive: findings that imply future outcomes or risks (e.g.,
1154 20     ↳ "high grade and lymphovascular invasion -> increased recurrence
1155 21     ↳ risk").
1156 22   - Prescriptive: specific, actionable recommendations based on
1157 23     ↳ findings (e.g., "recommend ER/PR testing", "suggest sentinel node
1158 24     ↳ biopsy").
1159 25   - Evaluative: judgements about prior interventions or response
1160 26     ↳ (e.g., "treatment effect present", "no residual tumor after
1161 27     ↳ therapy").
1162 28   - Exploratory: unexpected patterns or hypotheses worth further
1163 29     ↳ investigation (e.g., "discordant IHC vs morphology, consider
1164 30     ↳ molecular testing").
1165 31
1166 32 * For each insight you output, include these fields (concise,
1167 33   ↳ machine-parseable text inside the tag):
1168 34   - Type: one of the six categories above.
1169 35   - Insight: a concise 1 to 3 sentence paragraph that combines the
1170 36     ↳ observation (summary) and any actionable recommendation. If no
1171 37     ↳ recommendation, end with "Recommendation: none".
1172 38   - Evidence: brief quoted text or paraphrase from the report that
1173 39     ↳ supports the insight (include enough context to locate it).
1174 40   - Confidence: a numeric estimate from 0.0 to 1.0 reflecting how
1175 41     ↳ directly the report supports the insight.
1176 42
1177 43 * Output rules (strict):
1178 44   - Each insight must be emitted as a separate
1179 45     ↳ '<insight>...</insight>' block.
1180 46   - Inside each 'insight' block, present fields in this exact order
1181 47     ↳ and simple 'key: value' format (no extra markup):
1182 48     'Type: ...; Insight: ...; Evidence: "..."; Confidence: X.X'
1183 49   - Do NOT include any text outside the 'insight' tags. Your entire
1184 50     ↳ reply must consist only of one or more '<insight>...</insight>'
1185 51     ↳ blocks and nothing else.
1186 52   - Produce **all** insights you can extract; do not omit findings
1187 53     ↳ because they seem minor.
1188 54
1189 55 Refer to these examples (valid outputs):
1190 56
1191 57 Example - Descriptive:
1192 58 <insight>Type: Descriptive; Insight: The specimen is a left lower
1193 59   ↳ lobectomy containing a 2.3 cm invasive adenocarcinoma;
1194 60   ↳ Recommendation: none. Evidence: "LEFT LOWER LOBECTOMY...invasive
1195 61   ↳ adenocarcinoma 2.3 cm"; Confidence: 0.95</insight>
1196 62
1197 63 Example - Predictive (combined):
1198 64

```

```

1188 37 <insight>Type: Predictive; Insight: High-grade morphology with
1189   ↪ identified lymphovascular invasion suggests increased recurrence
1190   ↪ risk; Recommendation: consider close surveillance and discuss
1191   ↪ adjuvant therapy options. Evidence: "high grade" and
1192   ↪ "lymphovascular invasion identified"; Confidence: 0.80</insight>
1193 38 Example - Prescriptive (combined):
1194 39 <insight>Type: Prescriptive; Insight: ER/PR status not reported while
1195   ↪ invasive carcinoma is present, so hormone-receptor testing is
1196   ↪ needed; Recommendation: order ER/PR IHC. Evidence: "ER/PR not
1197   ↪ reported; invasive carcinoma described"; Confidence: 0.70</insight>
1198
1199
1200
1201 1 Given the following insight type:
1202 2 <type>{type}</type>
1203 3
1204 4 Given the following insight text:
1205 5 <insight>{insight}</insight>
1206 6
1207 7 Given the following Evidence in the cancer pathology report text:
1208 8 <evidence>{evidence}</evidence>
1209 9
1210 10 Instructions:
1211 11 * You will be given information on a single pathology insight (insight
1212   ↪ type, insight text, and corresponding Evidence excerpt from the
1213   ↪ cancer pathology report).
1214 12 * Task: produce **one** clear, concise question (ending with a question
1215   ↪ mark) that - if answered by inspecting the original pathology
1216   ↪ report - would enable an analyst to derive the given insight.
1217 13 * Constraints for the generated question:
1218   - It **must end with a single question mark**.
1219   - **Do not** include any verbatim text or specific phrases from the
1220     ↪ 'Evidence' field (no quoting or restating report fragments).
1221   - **Do not** perform analysis or give extraction rules inside the
1222     ↪ question - the question should ask *what to check* or *what
1223     ↪ confirmation is needed*, not how to compute it.
1224   - Prefer a single sentence; be specific enough to guide an analyst
1225     ↪ but keep wording generic (refer to "report fields",
1226     ↪ "measurements", "descriptors", etc., rather than quoting report
1227     ↪ content).
1228   - The question should be relevant to the insight's 'Type':
1229     ↪ Descriptive, Diagnostic, Predictive, Prescriptive, Evaluative,
1230     ↪ Exploratory.
1231 19 * Output format (strict):
1232   - Return exactly one '<question>...</question>' tag containing only
1233     ↪ the question text (nothing else).
1234 20
1235 21
1236 22 Example output (acceptable):
1237 23 <question>...</question>
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2295
2296
2297
2298
2299
2300
2301
2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348
2349
2350
2351
2352
2353
2354
2355
2356
2357
2358
2359
2360
2361
2362
2363
2364
2365
2366
2367
2368
2369
2370
2371
2372
2373
2374
2375
2376
2377
2378
2379
2380
2381
2382
2383
2384
2385
2386
2387
2388
2389
2390
2391
2392
2393
2394
2395
2396
2397
2398
2399
2400
2401
2402
2403
2404
2405
2406
2407
2408
2409
2410
2411
2412
2413
2414
2415
2416
2417
2418
2419
2420
2421
2422
2423
2424
2425
2426
2427
2428
2429
2430
2431
2432
2433
2434
2435
2436
2437
2438
2439
2440
2441
2442
2443
2444
2445
2446
2447
2448
2449
2450
2451
2452
2453
2454
2455
2456
2457
2458
2459
2460
2461
2462
2463
2464
2465
2466
2467
2468
2469
2470
2471
2472
2473
2474
2475
2476
2477
2478
2479
2480
2481
2482
2483
2484
2485
2486
2487
2488
2489
2490
2491
2492
2493
2494
2495
2496
2497
2498
2499
2500
2501
2502
2503
2504
2505
2506
2507
2508
2509
2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
2523
2524
2525
2526
2527
2528
2529
2530
2531
2532
2533
2534
2535
2536
2537
2538
2539
2540
2541
2542
2543
2544
2545
2546
2547
2548
2549
2550
2551
2552
2553
2554
2555
2556
2557
2558
2559
2560
2561
2562
2563
2564
2565
2566
2567
2568
2569
2570
2571
2572
2573
2574
2575
2576
2577
2578
2579
2580
2581
2582
2583
2584
2585
2586
2587
2588
2589
2590
2591
2592
2593
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607
2608
2609
2610
2611
2612
2613
2614
2615
2616
2617
2618
2619
2620
2621
2622
2623
2624
2625
2626
2627
2628
2629
2630
2631
2632
2633
2634
2635
2636
2637
2638
2639
2640
2641
2642
2643
2644
2645
2646
2647
2648
2649
2650
2651
2652
2653
2654
2655
2656
2657
2658
2659
2660
2661
2662
2663
2664
2665
2666
2667
2668
2669
2670
2671
2672
2673
2674
2675
2676
2677
2678
2679
2680
2681
2682
2683
2684
2685
2686
2687
2688
2689
2690
2691
2692
2693
2694
2695
2696
2697
2698
2699
2700
2701
2702
2703
2704
2705
2706
2707
2708
2709
2710
2711
2712
2713
2714
2715
2716
2717
2718
2719
2720
2721
2722
2723
2724
2725
2726
2727
2728
2729
2730
2731
2732
2733
2734
2735
2736
2737
2738
2739
2740
2741
2742
2743
2744
2745
2746
2747
2748
2749
2750
2751
2752
2753
2754
2755
2756
2757
2758
2759
2760
2761
2762
2763
2764
2765
2766
2767
2768
2769
2770
2771
2772
2773
2774
2775
2776
2777
2778
2779
2780
2781
2782
2783
2784
2785
2786
2787
2788
2789
2790
2791
2792
2793
2794
2795
2796
2797
2798
2799
2800
2801
2802
2803
2804
2805
2806
2807
2808
2809
2810
2811
2812
2813
2814
2815
2816
2817
2818
2819
2820
2821
2822
2823
2824
2825
2826
2827
2828
2829
2830
2831
2832
2833
2834
2835
2836
2837
2838
2839
2840
2841
2842
2843
2844
2845
2846
2847
2848
2849
2850
2851
2852
2853
2854
2855
2856
2857
2858
2859
2860
2861
2862
2863
2864
2865
2866
2867
2868
2869
2870
2871
2872
2873
2874
2875
2876
2877
2878
2879
2880
2881
2882
2883
2884
2885
2886
2887
2888
2889
2890
2891
2892
2893
2894
2895
2896
2897
2898
2899
2900
2901
2902
2903
2904
2905
2906
2907
2908
2909
2910
2911
2912
2913
2914
2915
2916
2917
2918
2919
2920
2921
2922
2923
2924
2925
2926
2927
2928
2929
2930
2931
2932
2933
2934
2935
2936
2937
2938
2939
2940
2941
2942
2943
2944
2945
2946
2947
2948
2949
2950
2951
2952
2953
2954
2955
2956
2957
2958
2959
2960
2961
2962
2963
2964
2965
2966
2967
2968
2969
2970
2971
2972
2973
2974
2975
2976
2977
2978
2979
2980
2981
2982
2983
2984
2985
2986
2987
2988
2989
2990
2991
2992
2993
2994
2995
2996
2997
2998
2999
3000
3001
3002
3003
3004
3005
3006
3007
3008
3009
3010
3011
3012
3013
3014
3015
3016
3017
3018
3019
3020
3021
3022
3023
3024
3025
3026
3027
3028
3029
3030
3031
3032
3033
3034
3035
3036
3037
3038
3039
3040
3041
3042
3043
3044
3045
3046
3047
3048
3049
3050
3051
3052
3053
3054
3055
3056
3057
3058
3059
3060
3061
3062
3063
3064
3065
3066
3067
3068
3069
3070
3071
3072
3073
3074
3075
3076
3077
3078
3079
3080
3081
3082
3083
3084
3085
3086
3087
3088
3089
3090
3091
3092
3093
3094
3095
3096
3097
3098
3099
3100
3101
3102
3103
3104
3105
3106
3107
3108
3109
3110
3111
3112
3113
3114
3115
3116
3117
3118
3119
3120
3121
3122
3123
3124
3125
3126
3127
3128
3129
3130
3131
3132
3133
3134
3135
3136
3137
3138
3139
3140
3141
3142
3143
3144
3145
3146
3147
3148
3149
3150
3151
3152
3153
3154
3155
3156
3157
3158
3159
3160
3161
3162
3163
3164
3165
3166
3167
3168
3169
3170
3171
3172
3173
3174
3175
3176
3177
3178
3179
3180
3181
3182
3183
3184
3185
3186
3187
3188
3189
3190
3191
3192
3193
3194
3195
3196
3197
3198
3199
3200
3201
3202
3203
3204
3205
3206
3207
3208
3209
3210
3211
3212
3213
3214
3215
3216
3217
3218
3219
3220
3221
3222
3223
3224
3225
3226
3227
3228
3229
3230
3231
3232
3233
3234
3235
3236
3237
3238
3239
3240
3241
3242
3243
3244
3245
3246
3247
3248
3249
3250
3251
3252
3253
3254
3255
3256
3257
3258
3259
3260
3261
3262
3263
3264
3265
3266
3267
3268
3269
3270
3271
3272
3273
3274
3275
3276
3277
3278
3279
3280
3281
3282
3283
3284
3285
3286
3287
3288
3289
3290
3291
3292
3293
3294
3295
3296
3297
3298
3299
3300
3301
3302
3303
3304
3305
3306
3307
3308
3309
3310
3311
3312
3313
3314
3315
3316
3317
3318
3319
3320
3321
3322
3323
3324
3325
3326
3327
3328
3329
3330
3331
3332
3333
333
```

```

1242 9 - Capture the shared analytic direction and primary objectives
1243 9 → implied by the question set (what analysts should aim to discover
1244 9 → or correlate in pathology images).
1245 10 - Be actionable at a high level (indicate the types of analyses or
1246 10 → correlations to prioritize) but avoid implementation details,
1247 10 → extraction rules, or step-by-step methods.
1248 11 - Balance scope: neither overly broad nor overly detailed - enough
1249 11 → to guide design of image-analysis workflows and hypothesis
1249 11 → generation.
1250 12 - Reflect clinical relevance (e.g., link morphology to
1251 12 → outcome/markers, flag ambiguous cases for review) and encourage
1252 12 → validation/uncertainty handling, without prescribing exact
1252 12 → thresholds.
1253 13
1254 14 * Constraints:
1255 15   - Produce a single paragraph, 1 to 2 sentences long (preferably 15
1256 15 → to 40 words).
1257 16   - Do NOT restate or quote the input questions; synthesize their
1257 16 → themes instead.
1258 17   - Do NOT include bullets, lists, or extra commentary.
1259 18   - The output must be strictly enclosed in a single '<goal></goal>'
1259 18 → tag and contain only that tag and the Goal text.
1260 19
1261 20 Example output (acceptable):
1262 21 <goal>...</goal>
1263 21
1264
1265 Prompts in MedInsightAgent. Prompt 5, Prompt 6, Prompt 7, Prompt 8, Prompt 9 and Prompt 10
1266 present the detailed prompts for different parts of MedInsightAgent.
1267
1268 Prompt 5: Prompt for the Image Summarization Module in Visual Root Finder.
1269 1 You are given a single pathology image of a cancerous tissue (H&E
1270 1 → slide), and your task is to produce a concise, clinically useful
1270 1 → summary describing what is seen.
1271 2 Do not invent clinical history or definitive diagnoses beyond what the
1272 2 → image supports - state uncertainty where appropriate.
1273 3
1274 4 Output guidance (high-level, not rigid formatting):
1275 5   * A short summary (brief - about 1-3 sentences) describing the main
1276 5 → histologic features visible at low magnification (e.g., staining,
1276 5 → overall architecture, areas of increased cellularity, gland
1277 5 → formation, necrosis, infiltration of surrounding tissue).
1278 6   * A short list of 3-6 keywords highlighting the most important features.
1278 6 → Each keyword must be enclosed within <keyword></keyword> tags.
1279 7   * One brief recommendation of next steps for diagnostic confirmation
1279 7 → (e.g., examine higher-power fields, perform immunohistochemistry
1280 7 → panels, correlate with clinical data).
1281 7
1282 7
1283
1284 Prompt 6: Prompt for the Root Question Generator in Visual Root Finder.
1285 1 Given the following context:
1286 1 <context>{context}</context>
1287 1
1288 4 Given the following goal:
1288 5 <goal>{goal}</goal>
1289 6
1290 7 Given the cancer pathology image.
1291 8
1292 9 Given the summary of the image:
1292 10 <summary>{image_summary}</summary>
1293 11
1294 12 Given the searching results of the image summary:
1294 13 <search_results>{search_results}</search_results>
1295 13
1296 14

```

```

1296 15 Instructions:
1297 16 * Write a list of questions to be solved by your cancer pathology team
1298 17   ↪ to analyze the provided cancer histopathology images and reach the
1299 18   ↪ stated goal.
1300 19 * Focus questions on image-derived evidence (slide-level labels,
1301 20   ↪ region/patch-level features, cellular and tissue morphology, tumor
1302 21   ↪ microenvironment, staining characteristics, magnification/scale,
1303 22   ↪ annotation masks) and any linked metadata (diagnosis, clinical
1304 23   ↪ outcomes, molecular markers, patient demographics).
1305 24 * Explore diverse aspects of the image data and metadata, and ask
1306 25   ↪ questions that are directly relevant to the goal.
1307 26 * To better understand and analyze the cancer pathology image, you can
1308 27   ↪ refer to the given summary of the image and the search results.
1309 28 * You must ask the right questions to surface anything interesting in
1310 29   ↪ the pathology images (morphological trends, spatial patterns, rare
1311 30   ↪ anomalies, artifacts, staining variability,
1312 31   ↪ segmentation/annotation issues, correlations with outcomes, etc.).
1313 32 * Make sure each question can realistically be answered using the
1314 33   ↪ available data schema (image tiles/patches, labels, annotations,
1315 34   ↪ clinical/molecular metadata, quality metrics).
1316 35 * Note that the insights your team extracts will be used to generate a
1317 36   ↪ clinical/research report.
1318 37 * Each question should be a single-part question that requires a single
1319 38   ↪ direct answer - end the line with exactly one '?' and avoid
1320 39   ↪ compound questions.
1321 40 * Do not number the questions.
1322 41 * You can produce at most {max_questions} questions. Stop generating
1323 42   ↪ after that.
1324 43 * Most importantly, each question must be enclosed within
1325 44   ↪ <question></question> tags.
1326 45
1327 46 Example response:
1328 47 <question>What is the tumor status and the size of the submitted lymph
1329 48   ↪ node from the station 7 biopsy?</question>
1330 49 <question>Does the clinical history provided in the report align with
1331 50   ↪ the pathological diagnosis regarding the specific type of
1332 51   ↪ malignancy?</question>

```

1328 52 Prompt 7: Prompt for the Image Analysis Tool in Analytical Insight Agent.

```

1330 1 ##### Instruction:
1331 2 Given the following Question:
1332 3 <question>{question}</question>
1333 4
1334 5 Given: one cancer pathology image (the input image) to be inspected to
1335 6   ↪ answer the question.
1336 7 Task (what to do):
1337 8 * Analyze the image with the Question above as the analytic objective.
1338 9   ↪ Your job is to extract the **key image-derived information** that
1339 10   ↪ directly relates to answering the Question, describe the visual
1340 11   ↪ evidence, identify the image regions to inspect, note ambiguities
1341 12   ↪ or limitations, and recommend next steps (additional images,
1342 13   ↪ stains, metadata, or human review) required to confidently answer
1343 14   ↪ the Question.
1344 15 Required content to produce (use these exact field names and order
1345 16   ↪ inside the output tag):
1346 17 1. 'KeyImageFindings:' 26 concise short sentences describing the
1347 18   ↪ essential visual features observed that relate to the Question
1348 19   ↪ (morphology, pattern, structures, presence/absence of features).
1349 20 2. 'RegionsOfInterest:' brief textual description of where in the image
1350 21   ↪ the evidence appears (e.g., "upper-left field, dense invasive
1351 22   ↪ nests near adipose boundary") or integer pixel/bbox coordinates if
1352 23   ↪ available; if none, write 'none'.

```

1350 13 3. 'Measurements:' any quantitative values you can extract/estimate
1351 1351 ↳ from the image relevant to the Question (size in mm if slide scale
1352 1352 ↳ known, % area, counts); if none, write 'none'.
1353 14 4. 'AmbiguitiesOrLimitations:' concise notes on what prevents a
1354 1354 ↳ definitive answer (e.g., low resolution, focal artifact, required
1355 1355 ↳ IHC not visible, missing context).
1356 15 5. 'RecommendedNextSteps:' 13 short actionable recommendations to
1357 1357 ↳ resolve ambiguities (e.g., request additional WSI, perform IHC for
1358 1358 ↳ marker X, consult pathologist).
1359 16 6. 'Confidence:' numeric score between 0.0 and 1.0 (one decimal place),
1360 1360 ↳ estimating how confidently the image evidence supports the
1361 1361 ↳ KeyImageFindings and a direct answer to the Question.
1362 17 Constraints & style:
1363 1363 * Keep each field concise. Use clinical/technical wording but keep
1364 1364 ↳ sentences short (one line each preferred).
1365 1365 * Assume common OCR errors and slide variability; be explicit if that
1366 1366 ↳ affects interpretability.
1367 1367 * Do NOT include any narrative or extra commentary outside the required
1368 1368 ↳ fields.
1369 1369 Output rules (strict):
1370 1370 * Your final reply must contain **only** a single
1371 1371 ↳ '**<findings>...</findings>**' tag and nothing else.
1372 1372 * Inside the 'findings' tag, present the fields in the exact order and
1373 1373 ↳ format below, separated by semicolons (';') no other punctuation
1374 1374 ↳ structure, no newlines outside the tag:
1375 1375 'AnswerableFromImage: ...; KeyImageFindings: ...; RegionsOfInterest:
1376 1376 ↳ ...; Measurements: ...; AmbiguitiesOrLimitations: ...;
1377 1377 ↳ RecommendedNextSteps: ...; Confidence: X.X'
1378 1378 * All text must be replaceable by a downstream parser (avoid extra
1379 1379 ↳ colons or parentheses inside field contents unless necessary).
1380 1380 Refer to these examples (valid outputs):
1381 1381 Example:
1382 1382 <findings>KeyImageFindings: Invasive glandular clusters with prominent
1383 1383 ↳ nucleoli and desmoplastic stroma; RegionsOfInterest: central-right
1384 1384 ↳ field near tissue edge; Measurements: largest tumor focus approx.
1385 1385 ↳ 2.4 mm (estimated); AmbiguitiesOrLimitations: slide scale
1386 1386 ↳ approximate, focal crush artifact; RecommendedNextSteps: confirm
1387 1387 ↳ tumor size on full WSI and report scale, consider correlate with
1388 1388 ↳ IHC if marker-specific question; Confidence: 0.8</findings>

1387 Prompt 8: Prompt for the Answers & Insights Generator in Analytical Insight Agent

1 You are trying to answer a question based on information provided. This
2 → is a cancer pathology image data that could potentially consist of
3 → interesting insights
4
5 Given the goal:
6 <goal>{goal}</goal>
7
8 Given the question:
9 <question>{question}</question>
10
11 Given the analysis (if has):
12 <analysis>{analysis}</analysis>
13
14 Given the cancer pathology image.
15 Instructions:
16 * Based on the analysis and other information provided above, and
17 → analyze the provided cancer histopathology image, please write an
18 → answer to the question enclosed with <question></question> tags.

```

1404 16 * The answer should be a single sentence, but it should not be too
1405   ↳ high-level and should include the key details from the
1406   ↳ justification.
1407 17 * Output must use HTML-like tags in this order: first the answer between
1408   ↳ <answer></answer> tags, then the justification between
1409   ↳ <justification></justification> tags, then the insight between
1410   ↳ <insight></insight> tags. Do not output any other text outside
1411   ↳ these tags.
1412 18 * The justification should concisely summarize the image-derived
1413   ↳ evidence and any relevant linked metadata (e.g., morphology,
1414   ↳ cellular atypia, mitotic figures per high-power field, necrosis
1415   ↳ extent, spatial patterns, immunostain results, tumor fraction,
1416   ↳ clinical outcome) that support the answer keep it short (13
1417   ↳ sentences).
1418 19 * Use only information that can be derived from the provided
1419   ↳ histopathology images and linked metadata; do not invent patient
1420   ↳ details or data.
1421 20 * The entire response must be factual, precise about uncertainty (if
1422   ↳ any), and suitable for inclusion in a clinical/research report.
1423 21 * The insight should be a single, non-trivial, concise, and meaningful
1424   ↳ conclusion phrased in lay terms, grounded in the question, goal,
1425   ↳ and cancer histopathology image.
1426 22 * The insight should be something interesting and grounded based on the
1427   ↳ question, goal, and cancer histopathology image, something that
1428   ↳ would be interesting.
1429 23 * Refer to the following example response for the format of the answer,
1430   ↳ justification, and insight.
1431 24
1432 25 Example response:
1433 26 <answer>This is a sample answer</answer>
1434 27 <justification>This is a sample justification</justification>
1435 28 <insight>This is a sample insight</insight>
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457

```

Prompt 9: Prompt for the Follow-Up Question Generator in Follow-Up Question Composer.

```

1 Given the following context:
2 <context>{context}</context>
3
4 Given the following goal:
5 <goal>{goal}</goal>
6
7 Given the question and answer:
8 <question>{question}</question>
9 <answer>{answer}</answer>
10
11 Given the cancer pathology image.
12
13 Given the summary of the image:
14 <summary>{image_summary}</summary>
15
16 Given the searching results of the image summary:
17 <search_results>{search_results}</search_results>
18
19 Instructions:
20 * Produce a list of follow-up questions to explore the provided cancer
21   ↳ histopathology image and reach the stated goal.
22 * Note that we have already answered the question and have the answer;
23   ↳ do not include a question similar to the one above.
24 * Explore diverse aspects of the cancer histopathology image, and ask
25   ↳ questions that are relevant to my goal.
26 * To better understand and analyze the cancer pathology image, you can
27   ↳ refer to the given summary of the image and the search results.
28 * You must ask the right questions to surface anything interesting in
29   ↳ the pathology images (morphological trends, spatial patterns, rare

```

```

1458     ↳ anomalies, artifacts, staining variability,
1459     ↳ segmentation/annotation issues, correlations with outcomes, etc.).
1460 25 * Focus questions on image-derived evidence (slide-level labels,
1461     ↳ region/patch-level features, cellular and tissue morphology, tumor
1462     ↳ microenvironment, staining characteristics, magnification/scale,
1463     ↳ annotation masks) and any linked metadata (diagnosis, clinical
1464     ↳ outcomes, molecular markers, patient demographics).
1465 26 * Note that the insights your team extracts will be used to generate a
1466     ↳ clinical/research report.
1467 27 * Each question that you produce must be enclosed in
1468     ↳ <question></question> tags.
1469 28 * Each question should be a single-part question that requires a single
1470     ↳ direct answer end the line with exactly one '?' and avoid
1471     ↳ compound questions.
1472 29 * Do not number the questions.
1473 30 * You can produce at most {max_questions} questions. Stop generating
1474     ↳ after that.
1475 31 Example response:
1476 32 <question>What is the tumor status and the size of the submitted lymph
1477     ↳ node from the station 7 biopsy?</question>
1478 34 <question>Does the clinical history provided in the report align with
1479     ↳ the pathological diagnosis regarding the specific type of
1480     ↳ malignancy?</question>

```

Prompt 10: Prompt for the Question Selector in Follow-Up Question Composer.

```

1481 1 Given the information below:
1482 2 <context>{context}</context>
1483 3
1484 4 <goal>{goal}</goal>
1485 5
1486 6 <prev_questions>{prev_questions_formatted}</prev_questions>
1487 7
1488 8 <followup_questions>{followup_questions_formatted}</followup_questions>
1489 9
1490 10 Instructions:
1491 11 * Given a context and a goal, select one follow-up question from the
1492     ↳ above list to explore after prev_question that will help me reach
1493     ↳ my goal.
1494 12 * Do not select a question similar to the previous questions above.
1495 13 * Output only the index of the question in your response inside
1496     ↳ <question_id></question_id> tag.
1497 14 * The output questions ID must be 0-indexed.
1498 15
1499 16 Example response:
1500 17 <question_id>0</question_id>

```

G THE USE OF LARGE LANGUAGE MODELS (LLMs)

We acknowledge the use of large language models (LLMs) as auxiliary tools in the preparation of this work, primarily in the following aspects:

1. Dataset construction: During the dataset development process, we adopted an LLM-assisted approach combined with manual review. Specifically, LLMs were employed to refine and streamline the prompts used in data collection.
2. Manuscript preparation: LLMs were utilized for word choice and grammar checking, as well as for polishing the language throughout the writing of this manuscript.
3. The authors independently conceived and determined all research ideas, experimental designs, data analysis, and conclusions.